July 2024 in “JAAD Case Reports” Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.
April 2024 in “Bioactive materials” New microneedle treatment with growth factors and a hair loss drug shows better and faster hair growth results than current treatments.
3 citations
,
January 2025 in “JID Innovations” Hidradenitis suppurativa tunnels worsen the disease and often need surgery because current treatments are not very effective.
122 citations
,
April 2020 in “American Journal Of Pathology” Skin aging is a complex process influenced by various factors, leading to wrinkles and sagging, and should be considered a disease due to its health impacts.
July 2025 in “JAAD Case Reports” A thorough assessment and combined treatment are crucial for managing complex alopecia, especially in patients with skin of color.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
There are many treatments for common hair loss, but more trials are needed to decide which are best.
16 citations
,
July 2021 in “Histopathology” New markers and pathways have been found in skin tumors, helping better understand and diagnose them.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
2 citations
,
August 2020 in “Journal of Cosmetic Dermatology” Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
1 citations
,
May 2024 in “Dermatology and Therapy” Frontal Fibrosing Alopecia needs better diagnostics and treatments, with dutasteride showing promise.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
12 citations
,
April 2022 in “Dermatology and therapy” Alopecia areata leads to significantly higher healthcare costs due to more doctor visits and prescriptions.
2 citations
,
April 2025 in “Dermatology and Therapy” Alopecia areata affects quality of life more in adolescents than adults.
August 2025 in “American Journal of Clinical Dermatology” Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
3 citations
,
June 2022 in “Dermatology and therapy” A new botanical treatment improved hair growth and symptoms in lichen planopilaris patients.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
October 2025 in “Dermatology and Therapy” Recognizing and treating related skin conditions can improve atopic dermatitis management.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
5 citations
,
November 2024 in “Naunyn-Schmiedeberg s Archives of Pharmacology” miRNAs could help diagnose and treat gouty arthritis.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
February 2026 in “Eduvest - Journal Of Universal Studies” Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
Baricitinib effectively regrows hair in severe alopecia areata cases.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
9 citations
,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.